Valera Pharmaceuticals Receives Marketing Authorization In Denmark for VANTAS; Will Seek Approvals in Other EU Member Countries Through Mutual Recognition.CRANBURY, N.J. -- Valera Pharmaceuticals announced today that its subsidiary company, Valera Pharmaceuticals Ireland Limited, received marketing authorization from the Danish Medicines Agency for VANTAS(TM), its 12-month implant for the palliative treatment palliative treatment n. Treatment to alleviate symptoms without curing the disease. Palliative treatment A type treatment that does not provide a cure, but eases the symptoms. Mentioned in: Laparoscopy of advanced prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . VANTAS is currently marketed and sold in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. by Valera. The U.S. Food and Drug Administration approved VANTAS for sale and distribution in October 2004. David S. Tierney, MD, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Valera stated, "With today's announced approval of VANTAS by the Danish regulatory authority Noun 1. regulatory authority - a governmental agency that regulates businesses in the public interest regulatory agency administrative body, administrative unit - a unit with administrative responsibilities , we can begin seeking approvals in other EU member countries through the mutual recognition procedure as we continue to evaluate options for marketing VANTAS in Europe." About Valera Pharmaceuticals Valera Pharmaceuticals is a specialty pharmaceutical company concentrating on the development, acquisition and commercialization of products for the treatment of urological and endocrine conditions, diseases and disorders. Further information is available on the Internet at http://www.valerapharma.com/. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion